Skip to content

Study · Not a test of the peptide alone · 2010

3 results

Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.

Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C

The AAPS journal15 Jan 2010Cited by 7 (Europe PMC)

PMID20077053 (opens in a new tab)PMCIDPMC2844519 (opens in a new tab)DOI10.1208/s12248-009-9164-6 (opens in a new tab)PepBankPUB-20077053
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tesofensine.

  1. 01Computer modelNot a test of Tesofensine aloneIn silicoOther

    In modeling of Alzheimer patient data, a one-compartment model with first-order absorption and elimination adequately described tesofensine pharmacokinetics.

    In plain wordsIn computer analysis, a one-compartment model adequately described tesofensine absorption and elimination.

    Peptide
    Tesofensine
    Outcome
    Not applicableTesofensine pharmacokinetic model
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    For the PK, one-compartment models for tesofensine and M1 with first-order absorption and elimination were sufficient.
    2 context sentences
    Summary · context
    Retrospective population pharmacokinetic/pharmacodynamic (PK/PD) modeling of tesofensine, its metabolite M1, and assessment scale-cognitive subscale data from two 4-week placebo-controlled studies in 62 mild AD patients was performed using non-linear mixed effects modeling.
    Summary · context
    The final PK/PD model was used to predict data of a negative 14-week phase IIb PoC trial (430 AD patients).

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

  2. 02Computer modelNot a test of Tesofensine aloneIn silicoMechanism

    In modeling of Alzheimer patient data, an extended Emax model with disease progression best described the tesofensine pharmacokinetic-pharmacodynamic relationship.

    In plain wordsIn computer analysis, a model with disease progression best described tesofensine concentration-effect relationships.

    Peptide
    Tesofensine
    Outcome
    Not applicablePharmacokinetic-pharmacodynamic relationship
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    An extended Emax model including disease progression best described the PK/PD relationship using effect compartments.
    2 context sentences
    Summary · context
    Retrospective population pharmacokinetic/pharmacodynamic (PK/PD) modeling of tesofensine, its metabolite M1, and assessment scale-cognitive subscale data from two 4-week placebo-controlled studies in 62 mild AD patients was performed using non-linear mixed effects modeling.
    Summary · context
    The final PK/PD model was used to predict data of a negative 14-week phase IIb PoC trial (430 AD patients).

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

  3. 03Computer modelNot a test of Tesofensine aloneIn silicoOther

    In modeling of Alzheimer patient data, the tesofensine model successfully predicted the later proof-of-concept trial data.

    In plain wordsIn computer analysis, the tesofensine model successfully predicted the later trial data.

    Peptide
    Tesofensine
    Outcome
    Not applicableClinical outcome prediction
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    Various internal evaluation techniques confirmed the reliability and predictive performance of the PK/PD model, which also successfully predicted the 14-week PoC data.
    2 context sentences
    Summary · context
    Retrospective population pharmacokinetic/pharmacodynamic (PK/PD) modeling of tesofensine, its metabolite M1, and assessment scale-cognitive subscale data from two 4-week placebo-controlled studies in 62 mild AD patients was performed using non-linear mixed effects modeling.
    Summary · context
    The final PK/PD model was used to predict data of a negative 14-week phase IIb PoC trial (430 AD patients).

    In this study, Tesofensine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesofensine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.